While strong financial markets could create merger and acquisition headwinds for med tech, the volume of both M&As and deals are rising above each of the prior three years, indicating a growing industry interest that is not always clear in the financials.

As COVID-19 vaccinations continue to roll out, momentum builds with strong phase III data for what could become the fourth and fifth walls of defense in the U.S.

Med-tech M&A continued an upward trend through March, with 30% more completed in 2021 compared with this point last year. Deals, including collaborations, licensings and joint ventures, are up by 13%, although the value of those deals are trailing 2020 by 39%.

With the prevalence of central nervous system disorders such as Alzheimer’s disease, multiple sclerosis, epilepsy, Parkinson’s disease and stroke increasing annually, the need for novel therapeutics to treat neurologic and psychiatric disorders has never been greater. Unfortunately, even though there is a significant unmet medical need, because of the high risk and low approval rates of drugs targeting those devastating diseases, in the past decade big pharma companies have been dramatically reducing their R&D spending on CNS disorders, noted Naheed Kurji, president and CEO of Toronto-based Cyclica Inc.

More than doubling the amount raised by this point last month, med-tech financings are coming out strong in 2021, beating by 67% the early months of last year. The full year of 2020 broke med-tech financings records, reaching $59.7 billion. With $10.63 billion already raised this year, 2021 is well on its way to at least match last year’s amount.